TCBP (tcbiopharm.com) יחס שווי שוק לשווי בספרים

TC Biopharm aims for global leadership in the immunopharmaceuticals segment through the development of T-cell drugs, although sanctions and a logistics collapse are hindering British research. The current price-to-book ratio, where the parameter equals 0.25, visualizes these investor expectations. The situation is further complicated by a lack of revenue and a linear increase in expenditures for sterile laboratories as testing expands.

The ownership of its own cGMP plant in Scotland provides TC Biopharm with strategic manufacturing autonomy. By analyzing the change in the market capitalization-to-book value ratio, an investor assesses the market premium over the value of net assets. This coefficient measures the gap between the exchange price and the book value of the business. An increase in this metric reflects optimism regarding future earnings, whereas an excessive divergence signals a reduction in the capital margin of safety.